Rafferty Asset Management
SAGE

Rafferty Asset Management’s Sage Therapeutics SAGE Stock Holding History

Rafferty Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-149,114
Closed -$1.08M – 1171
2024
Q3 		$1.08M Buy
149,114
+25,855
+21% +$237K ﹤0.01% 786
2024
Q2 		$1.34M Sell
123,259
-269,166
-69% -$3.45M 0.01% 749
2024
Q1 		$7.35M Buy
392,425
+85,511
+28% +$1.97M 0.03% 369
2023
Q4 		$6.65M Sell
306,914
-104,990
-25% -$2.08M 0.03% 382
2023
Q3 		$8.48M Buy
411,904
+273,257
+197% +$7.89M 0.05% 266
2023
Q2 		$6.52M Sell
138,647
-27,084
-16% -$1.35M 0.04% 356
2023
Q1 		$6.95M Buy
165,731
+1,874
+1% +$80.6K 0.05% 296
2022
Q4 		$6.25M Sell
163,857
-1,096
-0.7% -$41.9K 0.05% 326
2022
Q3 		$6.46M Buy
164,953
+67,491
+69% +$2.61M 0.07% 256
2022
Q2 		$3.15M Sell
97,462
-77,086
-44% -$2.58M 0.03% 380
2022
Q1 		$5.78M Buy
174,548
+35,792
+26% +$1.35M 0.03% 345
2021
Q4 		$5.9M Buy
138,756
+65,963
+91% +$2.76M 0.03% 310
2021
Q3 		$3.23M Buy
72,793
+39,819
+121% +$1.83M 0.02% 436
2021
Q2 		$1.87M Sell
32,974
-9,354
-22% -$661K 0.01% 705
2021
Q1 		$3.17M Buy
42,328
+28,826
+213% +$2.36M 0.02% 454
2020
Q4 		$1.17M Sell
13,502
-22,101
-62% -$1.63M 0.01% 471
2020
Q3 		$2.18M Buy
35,603
+9,224
+35% +$467K 0.03% 393
2020
Q2 		$1.1M Buy
+26,379
New +$957K 0.02% 517
2020
Q1 		– Sell
-53,837
Closed -$3.89M – 768
2019
Q4 		$3.89M Buy
53,837
+13,276
+33% +$1.63M 0.06% 169
2019
Q3 		$5.69M Buy
40,561
+12,189
+43% +$2.04M 0.09% 138
2019
Q2 		$5.2M Sell
28,372
-4,492
-14% -$766K 0.09% 155
2019
Q1 		$5.23M Buy
+32,864
New +$4.76M 0.08% 132

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Rafferty Asset Management's SAGE Position: Q4 2024 in Review

Rafferty Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 149,114 shares — an estimated $1.08M sold.

Rafferty Asset Management first reported a position in SAGE in Q1 2019 and held it in 22 quarters. The position peaked at $8.48M in Q3 2023. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Rafferty Asset Management reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 149,114 Sage Therapeutics shares in Q4 2024, an estimated $1.08M.
  • Rafferty Asset Management first reported a position in Sage Therapeutics in Q1 2019 and held it in 22 quarters.
  • Rafferty Asset Management's Sage Therapeutics position peaked at $8.48M in Q3 2023.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Rafferty Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.